Matsutani A, Kaku K, Kaneko T
Diabetes. 1984 May;33(5):495-8. doi: 10.2337/diab.33.5.495.
Effect of tolbutamide on liver fructose-2,6-bisphosphate (F-2,6-P2) was examined in isolated perfused rat liver in situ with a flow-through method. Tolbutamide (1 mM) gradually increased liver F-2,6-P2 level from 7.4 +/- 1.6 to 21.2 +/- 1.6 pmol/mg wet wt for 20 min perfusion. The increase of liver F-2,6-P2 induced by tolbutamide was dose dependent and was significantly observed at 10 min perfusion. The maximum plateau level of F-2,6-P2 induced by 16.7 mM glucose was further increased with 1 mM tolbutamide. Glucagon (10(-11) M) decreased the elevated level induced by 16.7 mM glucose, but this effect was completely inhibited with 2 mM tolbutamide. Cyclic AMP level of the liver throughout the perfusion with tolbutamide did not change. Carboxytolbutamide or gliclazide perfusion did not change significantly the liver F-2,6-P2 level; however, the results suggest that tolbutamide may increase the liver F-2,6-P2 level by affecting the phosphorylation state of fructose-6-phosphate, 2-kinase/fructose-2,6-bisphosphatase through cyclic AMP-dependent protein kinase, resulting in the stimulation of glycolysis and the inhibition of gluconeogenesis in the liver. Thus, the extrapancreatic action and the mechanism of action of different sulfonylureas may differ.
采用连续灌注法,在原位分离灌注的大鼠肝脏中研究了甲苯磺丁脲对肝脏果糖 -2,6-二磷酸(F-2,6-P2)的影响。在灌注20分钟的过程中,甲苯磺丁脲(1 mM)使肝脏F-2,6-P2水平从7.4±1.6逐渐升高至21.2±1.6 pmol/mg湿重。甲苯磺丁脲诱导的肝脏F-2,6-P2升高呈剂量依赖性,在灌注10分钟时可明显观察到。16.7 mM葡萄糖诱导的F-2,6-P2最大平台水平在加入1 mM甲苯磺丁脲后进一步升高。胰高血糖素(10⁻¹¹ M)降低了16.7 mM葡萄糖诱导的升高水平,但这种作用在加入2 mM甲苯磺丁脲后被完全抑制。在整个甲苯磺丁脲灌注过程中,肝脏的环磷酸腺苷水平没有变化。羧基甲苯磺丁脲或格列齐特灌注对肝脏F-2,6-P2水平没有显著影响;然而,结果表明甲苯磺丁脲可能通过环磷酸腺苷依赖性蛋白激酶影响6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶的磷酸化状态,从而增加肝脏F-2,6-P2水平,导致肝脏糖酵解受到刺激,糖异生受到抑制。因此,不同磺脲类药物的胰腺外作用及其作用机制可能不同。